| We demonstrate the statistically significant efficacy of remdesivir in reducing the surrogate endpoint of the high-risk COVID-19 state by 34.8% for a 14-day period. |
| The result of the surrogate predicts the efficacy for the primary endpoint of COVID-19 death by 30.5% up to a 28-day period. |
| Remdesivir treatment results in a 34.3% significantly higher odds of discharge. |
| The findings support the early clinical use of remdesivir in treating COVID-19 patients. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.